Allergen Immunotherapy
LETI Pharma S.L.U. focuses on subcutaneous immunotherapy for allergic rhinoconjunctivitis, with research centered on clinical responses to house dust mite and pollen allergens.
- Dermatophagoides pteronyssinus and Dermatophagoides farinae
- Grass pollen immunotherapy
- Olive pollen immunotherapy
The sponsor’s trials examine treatment effects in patients with persistent nasal and ocular allergy symptoms, including those with controlled asthma.
Respiratory Allergy and Asthma
Clinical research activity includes patients with allergic rhinitis and allergic rhinoconjunctivitis, particularly when these conditions coexist with asthma.
- Moderate to severe persistent symptoms
- Seasonal pollen-related disease
- Controlled asthma comorbidity
Trials are designed around symptom burden during allergen exposure periods and the management of upper and lower airway allergic disease.
Pollen-Driven Seasonal Allergy
The sponsor investigates immunotherapy for grass and olive pollen-related disease, with emphasis on seasonal symptom control and medication use during peak exposure.
- Grass pollen sensitisation
- Olive pollen sensitisation
- Combined symptom and medication outcomes
Research activity reflects interest in clinically relevant sensitisation patterns that drive seasonal rhinoconjunctivitis.
House Dust Mite Allergy
LETI Pharma S.L.U. also funds studies in perennial allergy caused by house dust mite exposure, addressing ongoing symptoms outside the pollen season.
- Dust mite extract mixtures
- Persistent allergic rhinoconjunctivitis
- Asthma-associated allergy
This area extends the sponsor’s interest in both indoor and outdoor allergen-driven respiratory disease.
